Bacterial meningitis: current therapy and possible future treatment options

被引:0
作者
Woehrl, Bianca [2 ]
Klein, Matthias [2 ]
Grandgirard, Denis [1 ]
Koedel, Uwe [2 ]
Leib, Stephen [1 ]
机构
[1] Univ Bern, Inst Infect Dis, Neuroinfect Lab, CH-3010 Bern, Switzerland
[2] Univ Munich, Klinikum Grosshadern, Dept Neurol, Munich, Germany
基金
瑞士国家科学基金会;
关键词
complement; daptomycin; dexamethasone; matrix metalloproteinases; rifampicin; roscovitine; Streptococcus pneumoniae; EXPERIMENTAL PNEUMOCOCCAL MENINGITIS; CENTRAL-NERVOUS-SYSTEM; NONBACTERIOLYTIC ANTIBIOTIC DAPTOMYCIN; NEUROTROPHIC FACTOR BDNF; ALPHA CONVERTING-ENZYME; LIPOTEICHOIC ACID LTA; BLOOD-BRAIN-BARRIER; STREPTOCOCCUS-PNEUMONIAE; CEREBROSPINAL-FLUID; MATRIX METALLOPROTEINASES;
D O I
10.1586/ERI.11.129
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Despite targeted therapy, case-fatality rates and neurologic sequelae of bacterial meningitis remain unacceptably high. The poor outcome is mainly due to secondary systemic and intracranial complications. These complications seem to be both a consequence of the inflammatory response to the invading pathogen and release of bacterial components by the pathogen itself. Therefore, within the last decades, research has focused on the mechanism underlying immune regulation and the inhibition of bacterial lysis in order to identify new targets for adjuvant therapy. The scope of this article is to give an overview on current treatment strategies of bacterial meningitis, to summarize new insights on the pathophysiology of bacterial meningitis, and to give an outlook on new treatment strategies derived from experimental models.
引用
收藏
页码:1053 / 1065
页数:13
相关论文
共 125 条
[1]   Glycerol adjuvant therapy in adults with bacterial meningitis in a high HIV seroprevalence setting in Malawi: a double-blind, randomised controlled trial [J].
Ajdukiewicz, Katherine M. B. ;
Cartwright, Katharine E. ;
Scarborough, Matthew ;
Mwambene, James B. ;
Goodson, Patrick ;
Molyneux, Malcolm E. ;
Zijlstra, Eduard E. ;
French, Neil ;
Whitty, Christopher J. M. ;
Lalloo, David G. .
LANCET INFECTIOUS DISEASES, 2011, 11 (04) :293-300
[2]  
Assiri AM, 2009, MAYO CLIN PROC, V84, P403, DOI [10.4065/84.5.403, 10.1016/S0025-6196(11)60558-2]
[3]   Detrimental role of delayed antibiotic administration and penicillin-nonsusceptible strains in adult intensive care unit patients with pneumococcal meningitis: The PNEUMOREA prospective multicenter study [J].
Auburtin, Marc ;
Wolff, Michel ;
Charpentier, Julien ;
Varon, Emmanuelle ;
Le Tulzo, Yves ;
Girault, Christophe ;
Mohammedi, Ismael ;
Renard, Benoit ;
Mourvillier, Bruno ;
Bruneel, Fabrice ;
Ricard, Jean-Damien ;
Timsit, Jean-Francois .
CRITICAL CARE MEDICINE, 2006, 34 (11) :2758-2765
[4]   Effects of clinically used antioxidants in experimental pneumococcal meningitis [J].
Auer, M ;
Pfister, LA ;
Leppert, D ;
Täuber, MG ;
Leib, SL .
JOURNAL OF INFECTIOUS DISEASES, 2000, 182 (01) :347-350
[5]   Daptomycin: mechanisms of action and resistance, and biosynthetic engineering [J].
Baltz, Richard H. .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2009, 13 (02) :144-151
[6]   Brain-derived neurotrophic factor protects against multiple forms of brain injury in bacterial meningitis [J].
Bifrare, YD ;
Kummer, J ;
Joss, P ;
Täuber, MG ;
Leib, SL .
JOURNAL OF INFECTIOUS DISEASES, 2005, 191 (01) :40-45
[7]   Adjuvant glycerol is not beneficial in experimental pneumococcal meningitis [J].
Blaser, Cornelia ;
Klein, Matthias ;
Grandgirard, Denis ;
Wittwer, Matthias ;
Peltola, Heikki ;
Weigand, Michael ;
Koedel, Uwe ;
Leib, Stephen L. .
BMC INFECTIOUS DISEASES, 2010, 10
[8]   The role of complement in innate and adaptive immunity to pneumococcal colonization and sepsis in a murine model [J].
Bogaert, D. ;
Thompson, C. M. ;
Trzcinski, K. ;
Malley, R. ;
Lipsitch, M. .
VACCINE, 2010, 28 (03) :681-685
[9]   Neuroprotection by a caspase inhibitor in acute bacterial meningitis [J].
Braun, JS ;
Novak, R ;
Herzog, KH ;
Bodner, SM ;
Cleveland, JL ;
Tuomanen, EI .
NATURE MEDICINE, 1999, 5 (03) :298-302
[10]  
Braun JS, 2002, J CLIN INVEST, V109, P19